SecBot SecBot
8-K ·Filed Jul 24, 2026

VIR

Vir Biotechnology, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3mo ago SEC0001628280-26-049499
Actionable Insight • Neutral

Monitor for appointment of a permanent CFO and any updates on Vir Bio's pipeline or financial strategy. The interim CFO is an internal appointee with deep accounting experience, so near-term disruption is minimal.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.69
T+0 close · Jul 24, 2026 · via day close
Latest settled
+17.49%
T+60 · $10.21
Vs SPY
+13.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 24 $8.69entry
  2. T+1 · 4mo ago +1.27%α +1.24% · $8.80
  3. T+5 · 4mo ago +2.42%α +2.04% · $8.90
  4. T+20 · 3mo ago +12.54%α +8.92% · $9.78
  5. T+60 · 29d ago +17.49%α +13.76% · $10.21
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vir Biotechnology disclosed that CFO Jason O'Byrne will step down on August 3, 2026 to pursue another opportunity, with no disagreement cited. The company appointed Brent Sabatini, SVP and CAO, as interim principal financial officer effective the same date, and has initiated a search for a permanent successor. This is a routine executive transition with no financial impact disclosed.

Key Facts

  • CFO Jason O'Byrne resigning effective August 3, 2026 to pursue another opportunity
  • No disagreement with Vir Bio's operations, policies, or practices
  • Brent Sabatini appointed interim principal financial officer effective August 3, 2026
  • Sabatini will not receive any additional compensation for the interim role
  • Company has initiated a search for a permanent CFO

Financial Impact

No financial figures disclosed in the filing

Risk Factors

  • Prolonged CFO vacancy could impact investor confidence and financial planning
  • Potential for strategic shifts if a new CFO is brought in from outside

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (VIR), Batch item 10001628280-26-049499
Document: 0001628280-26-049499-index-headers.html0001628280-26-049499
Document: 0001628280-26-049499-index.html0001628280-26-049499
Document: 0001628280-26-049499.txt0001628280-26-049499
8-K Filing (VIR), Batch item 50001628280-26-049499
Document: 0001628280-26-049499-index-headers.html0001628280-26-049499
Document: 0001628280-26-049499-index.html0001628280-26-049499
Document: 0001628280-26-049499.txt0001628280-26-049499

Track record

36 reports on VIR

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
  3. Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
  4. Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
  5. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
  6. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
  7. Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
  8. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
  10. Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (9h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 24, 2026